返回 A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Awarded "Pudong Model Enterprise with Well-known Brand in International Trade"

[2017-08-11] 

Shanghai, China – On August 3, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") was awarded "Pudong Model Enterprise with Well-known Brand in International Trade" by Shanghai Pudong District Government during the China (Shanghai) Free Trade Zone & Pudong District Trade Facilitation Measure Press Conference.
 
Weihua Shen, Deputy Director of Shanghai Municipal Commission of Commerce, Fangzhou Lu, Deputy Director of China (Shanghai) Pilot Free Trade Zone Management Committee, member of the standing committee of Pudong District Committee, and Deputy Head of Pudong District, Danian Jian, Inspector of China (Shanghai) Pilot Free Trade Zone Management Committee, Guozhu Xie, Secretary of CPC Leadership Group of Shanghai Pudong Customs and Director of Shanghai Pudong Customs, and Xingwei Zou, Pudong Entry-Exit Inspection and Quarantine Bureau, attended the conference. In total, the conference gathered over 500 attendees from Shanghai Municipal Commission of Commerce, Shanghai Pudong Customs, Pudong Entry-Exit Inspection and Quarantine Bureau, other Pudong governmental departments, Pudong international trade companies, and industry associations. The conference aims to push forward the trade facilitation reform in Shanghai Free Trade Zone under the guidance of "the Plan to Comprehensively Deepen the Reform and Opening-up in China (Shanghai) Pilot Free Trade Zone" by the State Council, as well as to present the construction achievements of Shanghai Free Trade Zone and the Core Area of Pudong International Trade Center. 
 
Fangzhou Lu, Deputy Director of China (Shanghai) Pilot Free Trade Zone Management Committee, member of the standing committee of Pudong district committee, and Deputy Head of Pudong District, said: "Brand building is always listed among companies' core strategies as brand image plays an important role in business and trade. We are glad to see several Pudong companies have built internationally well-known brand, which help them to win market share and may hopefully lead more domestic companies to capture overseas markets."
 
Through years of growth and innovation, MicroPort® has become a premier multinational medical solution provider covering a broad range of business segments including orthopedics, cardiovascular, electrophysiology, endovascular, neurovascular, cardiac rhythm management, diabetes and endocrine management, surgical management, and others. With over 200 products currently approved for use in over 5,000 hospitals in Asia Pacific, Europe, America and etc., MicroPort® is contributing to a better world through its life-saving medical therapies and quality-improving care devices being used in patients every 15 seconds, to help save a life, or improve quality of life or create new life for nearly 10 million patients worldwide. MicroPort® set up production and R&D facilities in Shanghai, Jiangsu, Zhejiang, Beijing, Shenzhen, and Memphis of the US. By mergers and acquisition, MicroPort® is taking solid steps in becoming a truly global player. MicroPort® has a global workforce of more than 3,000 employees of which one third are overseas employees. MicroPort® is committed to becoming a patient-oriented global enterprise in minimally invasive and other emerging medical technology industries, and will actively respond to the "Belt and Road" initiative to introduce safe, effective, affordable, and high-end China-developed products to more patients worldwide.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 

[Prev]:MicroPort® Orthopedics Signs Strategic Agreement with Wiltrom Medical
[Next]:MicroPort® Orthopedics Holds the Second TKA Training Course in Hong Kong